M6PR and neoplasm: To determine whether M6PR shuttling is involved in the synergistic interaction between chemotherapy and T4 immunotherapy, we indirectly blocked its surface upregulation using 3-MA—an autophagy inhibitor which blocks the formation of autophagosomes and subsequent release of M6PR to the tumor cell surface.